Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-01-10 00:00:00 ET · period of report 2023-01-06 · accession 0001883850-23-000025 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-10 | 2023-01-06 | REGN | BROWN MICHAEL S | Dir | S - Sale+OE | $747.14 | -3,070 | 1,247 | -71% | -$2.29M |
| D | 2023-01-10 | 2023-01-06 | REGN | BROWN MICHAEL S | Dir | M - OptEx | $520.01 | +3,070 | 4,317 | +246% | +$1.60M |
| D | 2023-01-10 | 2023-01-06 | REGN | BROWN MICHAEL S | Dir | M - OptEx | $0.00 | -3,070 | 6,142 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-06 | S | D | 3,070 | $747.14 | 1,247 | D | — | — | (F2) Represents volume-weighted average price of sales of 3,070 shares of Company stock on January 6, 2023 at prices ranging from $747.00 to $747.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 6, 2023 at each separate price. |
| 2 | Common | Common Stock | 2023-01-06 | M | A | 3,070 | $520.01 | 4,317 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-01-06 | M | D | 3,070 | $0.00 | 6,142 | D | $520.01 · — to 2026-01-04 | 3,070 Common Stock | (F4) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. |